Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osilodrostat for hypertension due to hypercortisolaemia in Cushing's syndrome
2025-524649-28-00Phase 4Authorised
- Sponsor
- Recordati SpA
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, randomised, double-blind trial in Cushing's syndrome comparing Isturisa with Placebo (2 arms). Primary endpoint: 24-hour urinary free cortisol normalization at Week 30. Planned start Sep 2026; status: authorised.
02
Drugs
osilodrostat
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2025-524649-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524649-28-00.